Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21841789 | 1.00 | GAA (0.52) | GAAMEN1KMT2AMAPTRAB9A | |
| SCHEMBL21812330 | 1.00 | GAA (0.52) | GAAMEN1KMT2AMAPTRAB9A | |
| SCHEMBL21812493 | 0.83 | ALDH1A1 (0.46) | GAAMEN1KMT2AMAPTRAB9A | |
| SCHEMBL21812492 | 0.83 | ALDH1A1 (0.46) | GAAMEN1KMT2AMAPTRAB9A | |
| SCHEMBL21812481 | 0.80 | ALDH1A1 (0.71) | GAAMEN1KMT2AMAPTRAB9A | |
| SCHEMBL21812480 | 0.80 | ALDH1A1 (0.71) | GAAMEN1KMT2AMAPTRAB9A | |
| SCHEMBL15987828 | 0.72 | MEN1 (0.55) | GAAMEN1KMT2AMAPTRAB9A | |
| SCHEMBL15987829 | 0.72 | MEN1 (0.55) | GAAMEN1KMT2AMAPTRAB9A | |
| SCHEMBL7950232 | 0.72 | RAB9A (0.65) | GAAMEN1KMT2AMAPTRAB9A | |
| SCHEMBL20718863 | 0.72 | NPC1 (0.52) | GAAMEN1KMT2AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3856736-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020065048-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2020-04-02 | — | — | WO | disclosed |
| EP-3628669-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2020-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CYBB, NOX1, NOX4 | GAA 284/4885MEN1 4789/4885KMT2A 3673/4885 |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CYBB, NOX1, NOX4 | GAA 308/4885MEN1 4840/4885KMT2A 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.